IceCure Medical (NASDAQ:ICCM - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02, RTT News reports. IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%. The business had revenue of $0.73 million during the quarter, compared to analyst estimates of $0.75 million. During the same period in the prior year, the company posted ($0.08) earnings per share.
IceCure Medical Price Performance
ICCM traded up $0.02 during midday trading on Friday, reaching $1.05. 166,926 shares of the company's stock were exchanged, compared to its average volume of 475,826. The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02. The business has a 50-day simple moving average of $1.11 and a two-hundred day simple moving average of $1.14. The firm has a market capitalization of $58.28 million, a price-to-earnings ratio of -3.62 and a beta of 0.41. IceCure Medical has a one year low of $0.48 and a one year high of $1.66.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a "buy" rating and issued a $2.50 price target on shares of IceCure Medical in a report on Thursday.
Get Our Latest Stock Analysis on IceCure Medical
IceCure Medical Company Profile
(
Get Free Report)
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Featured Articles
Before you consider IceCure Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IceCure Medical wasn't on the list.
While IceCure Medical currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
